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Summary
Background: Analysis of trends in cancer survival in defined
well surveilled populations can provide useful indications on
advancements in cancer management and treatment.
Patients and methods: Survival rates from the Vaud Cancer
Registry were computed for 31,158 cases registered in 1984—
1993, and compared with those registered in 1974-1978 and
1979-1983.
Results: A systematic, albeit generally moderate, tendency
towards increasing five-year relative survival was observed for
both sexes and most major cancer sites, including oral cavity
and pharynx (0.38-0.43), stomach (0.21-0.26), colon (0.49-0.55),
rectum (0.45-0.51), lung (0.08-0.12), skin melanoma (0.67-0.89),
female breast (0.67-0.80), endometrium (0.72-0.84), ovary (0.28-
0.37). prostate (0.44-0.66), testis (0.73-0.96), bladder (0.31-
0.50), kidney and renal pelvis (0.41-0.59), thyroid (0.73-0.81),
non-Hodgkin's lymphomas (0.37-0.63), Hodgkin's disease (0.61-
0.81), and leukaemias (0.27-0.39). Survival for all cancers and
both sexes combined, rose from 0.51-0.64 (0.57 for males, 0.71
for females). No appreciable change in survival was observed
for cancers of oesophagus, liver, gallbladder, pancreas, larynx,
cervix uteri, brain, multiple myeloma, as well as unidentified
or unknown origin neoplasms.
Conclusions: Survival estimates for most cancer sites are
comparable to the US SEER dataset, and their pattern of
trends are discussed in terms of improved diagnosis and treat-
ment for various neoplasms.
Key words: cancer registry, neoplasms, population-based, sur-
vival, Switzerland, time trends
Introduction
Analysis of trends in cancer survival in a specific, well
surveilled population can provide useful indications on
advancements in cancer management and treatment. We
have analyzed survival for patients diagnosed with cancer
in the Swiss Canton of Vaud in the periods 1974-1978
and 1979-1983, showing only modest advancements in
survival for most cancer sites [1].
Over the last few years, cancer survival estimates
have been made available from the SEER Program of
the US National cancer Institute [2-4], the Finnish
Cancer Registry [5], as well as from the EUROCARE
project [6], which includes a network of European cancer
registration areas. These showed generally higher survival
rates from North America and substantial variations
within Europe, in the absence of a clear interpretation
[7].
It is therefore interesting to re-consider patterns and
trends in cancer survival from well defined and uni-
formly followed - over long time periods - populations.
In the present report, we update cancer survival figures
from the Vaud Cancer Registry, including patients diag-
nosed in the calendar periods 1984-1988 and 1989-1993.
Patients and methods
The data considered for this analysis were abstracted from the Vaud
Cancer Registry datafile, which includes data concerning incident
cases of malignant, and selected benign or borderline, neoplasms
diagnosed in the resident population of the Canton (whose population
in 1990 was about 602,000 inhabitants [8, 9]). Information systemati-
cally collected by the registry includes general demographic character-
istics of the patient (age, sex, municipality of residence), site and
histological type of the tumour according to the standard International
Classification of Diseases for Oncology (ICD-O) [10]), and time of
registration. A total of 53,203 invasive cancer cases registered between
1974 and 1993 were included in the present study, after exclusion of
2,475 cases either registered on death certificates alone (2.1% in the
Vaud Cancer registry datafile) [8, 9] or detected at death (2.3%). Table I
gives the distribution of cases considered according to cancer site (and
corresponding ICD-O), sex and the two most recent quinquennial
incidence calendar periods considered.
Information on survival was derived from mortality statistics and,
for 'apparently" non deceased cases, through an active follow-up based
on verification of vital status from registries of current residence. The
vital status of each registered case has thus been verified up to
December 31, 1998. Information on tumour stage was not available in
the global cancer registry dataset.
Survival curves were defined according to the product limit
(maximum likelihood. Kaplan and Meier) method [II] for four sub-
sequent calendar periods (i.e., 1974-1978,1979-1983,1984-1988, 1989-
1993). sex and age group ( < 6 0 and >60 years at diagnosis), and
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Table 1. Distribution of cases" according to cancer site (and corresponding ICD). sex and calendar period.
Cancer site
Mouth or pharynx
Oesophagus
Stomach
Colon
Rectum
Liver
Gallbladder and biliary tract
Pancreas
Larynx
Trachea, bronchus and lung
Bone
Connective tissue
Melanomatous skin cancer
Non-melanomatous skin cancer
Breast (females)
Cervix uteri
Corpus uteri
Ovary
Prostate
Testis
Bladder
Kidney and renal pelvis
Brain
Thyroid
Non-Hodgkin lymphomas
Hodgkin's disease
Multiple myeloma
Leukaemia
Childhood leukaemia (< 15 years)
Unknown origin
Total, all cancers
ICD
140-9
150
151
153
154
155
156
157
161
162
170
171
172
173
174
180
182
183
185
186
188
189.0-0.1
191
193
200, 202
201
203
204-8
204-8
195, 199
140-208
Number of cases
Males
1984-1988
396
155
242
413
268
99
47
166
140
1114
13
32
177
1855
-
_
-
-
833
120
306
151
88
20
229
35
77
142
9
172
7411
1989-1993
428
184
220
481
273
138
46
182
120
1189
19
37
231
2341
-
_
-
-
1166
142
340
188
93
24
299
37
61
143
10
169
8710
Females
1984-1988
79
52
141
453
243
29
80
166
15
236
9
37
212
1745
1629
160
279
238
-
_
95
105
76
73
175
33
58
121
10
151
6817
1989-1993
127
69
126
457
246
33
77
185
20
307
5
43
288
2320
2017
154
320
240
-
_
107
123
83
87
239
29
76
112
8
155
8220
a
 Only invasive tumours considered.
Results from Vaud Cancer Registry, Switzerland, 1984-1993.
differences between survival curves for the first and the last calendar
period were tested by means of the usual log-rank test [12, 13]. Five-
year survival was computed starting from the date of confirmation
(mostly histological verification) of the diagnosis. Relative survival
rates [14] were computed, after allowance for the general lifetables of
the canton [1].
Results
Table 2 gives the five-year crude survival rates - and
corresponding standard errors - from each cancer site
and sex diagnosed in the last two subsequent incidence
periods considered (1984-1988 and 1989-1993).
Table 3 gives five-year relative survival rates for each
cancer site and sex in 1974-1978, 1984-1988 and 1989-
1993. A systematic, albeit moderate, tendency towards
increasing survival was observed for both sexes and
most major cancer sites, including oral cavity and phar-
ynx (0.38-0.43), stomach (0.21-0.26), colon (0.49-0.55),
rectum (0.45-0.51), lung (0.08-0.12), skin melanoma
(from 0.67 to 0.89), female breast (0.67-0.80), endome-
trium (0.72-0.84), ovary (0.28-0.37), prostate (0.44-
0.66), testis (0.73-0.96), bladder (0.31-0.50), kidney and
renal pelvis (0.41-0.59), thyroid (0.73-0.81), non-Hodg-
kin's lymphomas (0.37-0.63), Hodgkin's disease (0.61—
0.81), and leukaemias (0.27-0.39). Survival for all
cancers and both sexes combined rose from 0.51 to 0.64
(0.57 for males, 0.71 for females). Excluding non-mela-
nomatous skin cancer, corresponding values rose from
0.31 to 0.43 for males, from 0.51 to 0.60 for females, and
from 0.41 to 0.51 for both sexes combined. The changes
observed in total cancer survival, however, also reflect
the different composition of cancer sites over time (i.e., a
relative decline in lung cancer and a rise in prostate
cancer in males; the decline in stomach but the propor-
tional rise in colorectal cancer). For a few common
cancer sites (e.g., stomach, prostate, cervix uteri and
ovary) survival increases were observed between 1984—
1988 and 1989-1993, after 15 years of substantial stability
or very modest improvement.
No appreciable change in survival, however, was
observed for several upper digestive tract sites, including
cancers of oesophagus (five-year relative survival rate in
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Table 2. Five-year product-limit crude survival rates from various cancers according to sex and calendar period.
Cancer site Males Females Total
1984-1988 1989-1993 1984-1988 1989-1993 1984-1988 1989-1993
Mouth or pharynx 0.34(0.02) 0.37(0.02) 0.44(0.06) 0.42(0.04) 0.36(0.02) 0.38(0.02)
Oesophagus 0.05(0.02) 0.08(0.02) 0.15(0.05) O.O6(O.O3)a 0.07(0.02) 0.07(0 02)
Stomach 0.15(0.02) 0.21(0.03) 0.15(0.03) 0.19(0.03) 0.15(0.02) O.?.0(002)b
Colon 0.39(0.02) 0.41 (0.02)b 0.40(0.02) 0.45(0.02) 0.40(0.02) 0.43(0.02)b
Rectum 0.35(0.03) 0 40(0.03)b 0.38(0.03) 0.42(0.03)b 0.37(0.02) 0.41 (0.02)c
Liver 0.02(0.01)" 0.07 (0.02)" - 0.06(0.04)° 0.02(0.01)a 0.06(0.02)
Gallbladder and biliary tract 0.09(0.04)" 0.07(0.04)" 0.12(0.04) 0.10(0.03) 0.10(0.03) 0.09(0.03)
Pancreas 0.01(0.01)" 0 03(0.01)" 0.01 (0.01)a 0.03(0.01)a 0.01(0.01)" 0.03(0.01)
Larynx 0.67(0.04) 0.49(0.05)° 0.47(0.13) 0.90(0.17)c 0.65(0.04) 0.55(0.04)
Trachea, bronchus and lung 0.09(0.01) 0.11(0.01) 0.12(0.02) 0.11(0.02) 0.10(0.01) 0.11(0.01)
Bone 0.62(0.13) 047(0.11) 0.67(0.16) 0.80(0.18)a 0.64(0.10) 0.54(0.10)
Connective tissue 0.70(0.08) 0.55(0.08) 0.59(0.08) 0.46(0.08) 0.64(0.06) 0.50(0.06)"
Melanomatous skin cancer 0.64(0.04) 0.70 (0.03)c 0.79(0.03) 0.87(0.02)c 0.72(0.02) 0.79 (0.02)c
Non-melanomatous skin cancer 0.75(0.01) 0.76(0.01)b 0.82(0.01) 0.82(0.01) 0.78(0.01) 0.79(0.01)b
Breast (females) - - 0.69(0.01) 0.72 (0.01)c
Cervix uteri - - 0.55(0.04) 0.62(0.04)
Corpus uteri - - 0.69 (0.03) 0.74 (0.02)
Ovary - - 0.28(0.03) 0.32(0.03)
Prostate 0 34(0.02) 0.47 (0.0l)c -
Testis 0.87(0.03) 0.94(0.02)° -
Bladder 0 38(0.03) 0.39(0.03) 0 35(0.05) 0.37(0.05) 0.37(0.02) 0.38(0.02)
Kidney and renal pelvis 0.36(0.04) 0.53(0.04)° 0.41(0.05) 0.41(0.04) 0.38(0.03) 0.48(0.03)b
Brain 0.28(0.05) 0.19(0.04) 0.20(0.05) 0.13(0.04) 0.24(0.03) 0.15(0.03)
Thyroid 0.80(0.09) 0.62(0.10) 0.89(0.04) 0.75(0.05)° 0.87(0.04) 0.72(0.04)°
Non-Hodgkin lymphomas 0.45(0.03) 0.51(0.03) 0.52(0.04) 0.54(0.03) 0.48(0.03) 0.53(0.02)°
Hodgkin's disease 0.77(0.07) 0.76(0.07)° 0 72(0.08) 0.83(0.07) 0.74(0.05) 0.79(0.05)
Multiple myeloma 0.22(0.05) 0.28(0.06) 0.40(0.06) 0.24(0.05) 0.28(0.04) 0.26(0.04)
Leukaemia 0.31(0.04) 0.35(0.04) 0 35(0.04) 0.30(0.04) 0.33(0.03) 0.33(0.03)
Childhood leukaemia (< 15 years) 0.65(0.17)a 0.80(0.13) 0.80(0.13) 0.75(0.15) 0.73(0.10) 0.78(0.10)
Unknown origin 0.05(0.02) 0.07(0.02) 0.08(0.02) 0.07(0.02) 0.06(0.01) 0.07(0.01)
Total, all cancers 0.41(0.01) 0.46(0.01)° 0.57(0.01) 0.61(0.01)° 0.48(0.00) 0.53(0.00)°
Total, skin non-melanoma excluded 0.30(0.01) 0.34(0.01)° 0.48(0.01) 0.51(0.01)° 0.38(0.00) 0.43(0.00)°
Standard error given within parentheses.
" Estimates based on less than five cases at the beginning of the interval; bP < 0.10; c P < 0.05.
Results from Vaud Cancer Registry, Switzerland, 1984-1993.
1989-1993: 0.09), larynx (0.64), as well as liver (0.08),
gallbladder (0.11), pancreas (0.04), cervix uteri (0.70),
brain (0.18), multiple myeloma (0.32), and unidentified
or unknown origin neoplasms (0.09).
Table 4 gives corresponding figures for two separate
age groups (< 60 and ^ 60 years). The tendency towards
improved survival for several cancer sites was observed
both before age 60 and at age 60 or over, although for
some neoplasms (including breast, ovary, prostate and
testis), it was apparently more marked in the younger
age group. For kidney and bladder cancer, however,
improvements in survival were observed, mostly in
males, both at younger and at elderly age. The differ-
ences were larger for lymphoid neoplasms, including
non-Hodgkin's lymphomas (0.48-0.78 under age 60,
0.28-0.52 at age ^60), Hodgkin's disease (0.68-0.85
under age 60; 0.24-0.45 at age ^60), and leukaemias
(0.29-0.50 under age 60; 0.26-0.31 at age ^ 60). Survival
for all cancers combined, except non-melanomatous skin
cancer, increased from 0.50 to 0.62 under age 60, and
from 0.35 to 0.45 at age ^ 60.
Figure 1 gives curves for the first (1974-1978) and the
last (1989-1993) incidence period for eight selected sites,
i.e., colon, lung, cutaneous melanoma, breast (females),
ovary, prostate, testis and Hodgkin's disease. Statisti-
cally significant improvement in survival across the
calendar period considered emerged for all these sites
according to the log-rank test.
Discussion
The present estimates, derived from a carefully followed
population and a structured network of data collection,
indicate that five-year survival has apparently increased
over the last two decades for several neoplasms in the
Vaud population, although the interpretations of these
findings are not obvious. Most trends of increased sur-
vival were steady over time, although the pattern for any
specific neoplasms may be influenced by random varia-
tion.
Diagnostic anticipation has almost certainly had
some role for cancers of the colorectum, prostate, breast
and melanoma, following the introduction of PSA
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Figure 1. Survival curves for selected cancer sites according to calendar period of incidence (1974-1978 versus 1989-1993). Incident cases from
the Vaud Cancer Registry. Switzerland, 1974 1993 (period 1974-1978: : period 1989 1993: ).
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Table 3. Five-year relative survival rates from various cancers according to sex and calendar period.
Cancer site
Mouth or pharynx
Oesophagus
Stomach
Colon
Rectum
Liver
Gallbladder and biliary tract
Pancreas
Larynx
Trachea, bronchus and lung
Bone
Connective tissue
Melanomatous skin cancer
Non-melanomatous skin cancer
Breast (females)
Cervix uteri
Corpus uteri
Ovary
Prostate
Testis
Bladder
Kidney and renal pelvis
Brain
Thyroid
Non-Hodgkin lymphomas
Hodgkin's disease
Multiple myeloma
Leukaemia
Childhood leukaemia (< 15 years)
Unknown origin
Total, all cancers
Total, skin non-melanoma excluded
Males
1974-
1978
0.35
0.08
0.20
0.48
0.39
NAa
0.15
0.04
0 66
0.08
0 45
0.54
061
0.94
_
-
-
-
0 44
0.73
0.31
0 42
0.23
0 68
0.40
0.55
0.25
0.25
0.36
0.18
0.43
0.31
1984-
1988
0.39
0.06
0.20
0.51
0.45
0.03b
0.11"
0.01b
0.78
0.11
0.67
0.74
0.75
0.95
-
-
-
-
0.49
0 90
0.50
0.43
0.30
0.88
0.55
0.80
0.28
0.37
0.65b
0.07
0.51
0.36
1989-
1993
0.42
0.10
0.27
0.53
0.51
0.08
0.08b
0.04b
0.57
0.12
0.53
0.64
0.81
0.97
_
-
-
0.66
0.96
0.51
0.66
0.22
0.70
0.61
0.79
0.37
0.42
0.80
0.09
0.57
0.43
Females
1974-
1978
0.50
0.06
0.23
0.49
0.52
0.22b
0.15
0.04
0.70
0.10
0.79
0.72
0.71
0.96
0.67
0.65
0.72
0.28
-
_
0.30
0.39
0.20
0.75
0.34
0.71
0.40
0.30
0.38
0.14
0.59
0.51
1984-
1988
0.50
0.18
0.14
0.50
0.47
NA
0.15
0.01b
0.52
0.13
0 72
0.63
0.87
0.98
0.77
0.61
0.78
0.32
-
_
0.44
0.47
0.21
0.97
0.62
0.76
0.42
0.41
0.80
0.09
0.66
0.56
1989-
1993
0.48
0.08b
0.24
0.57
0.51
0.07b
0.13
0.04b
1.00
0.12
0.86b
0.55
0.94
0.99
0.80
0.70
0.84
0.37
-
0.47
0.48
0 14
0.85
0.64
0.84
0.29
0.36
0.75
0.08
0.71
0.60
Total
1974-
1978
0.38
0.07
0.21
0.49
0 45
0 05b
0.15
0.04
0.67
0.08
0.57
0.66
0.67
0.95
_
-
-
-
-
_
0.31
0.41
0.21
0.73
0.37
0.61
0.32
0.27
0.36
0.16
0.51
0.41
1984-
1988
0.41
0.09
0.19
0.51
0.46
0.02"
0.13
0.01b
0.75
0.11
0.69
0.68
0.82
0.96
-
-
-
-
_
_
0.48
0.45
0.26
0.95
0.58
0.78
0.35
0.39
0.73
0.08
0.59
0.46
1989-
1993
0.43
0.09
0.26
0.55
0.51
0.08
0.11
0.04
0.64
0.12
0.60
0.59
0.89
0.98
-
-
-
-
-
_
0.50
0 59
0.18
0.81
0.63
0.81
0.32
0.39
0.78
0.09
0.64
0.51
a
 Probability not assessable.
b
 Estimates based on less than five cases at the beginning of the interval.
Results from Vaud Cancer Registry, Switzerland, 1974-1993.
(prostate-specific antigen), mammography, occult blood
tests and sigmoidoscopy, and a general increased aware-
ness towards early diagnosis of these neoplasms, even in
the absence of generalized standardized screening pro-
grams on a population level.
Earlier diagnosis - or changed diagnostic modalities
- have probably influenced the registered survival for
cancers of the kidney and bladder, too, since the treat-
ment for these neoplasms, and the corresponding mor-
tality rates [15, 16], have not substantially changed over
time. This includes more accurate definition of invasion
for bladder cancer, and more extensive use of abdominal
CT scan and echography in the diagnosis of kidney
cancer. Changed definition of the disease, with the inclu-
sion of early disease may have favourably influenced
trends in survival for skin melanoma [17] and lympho-
mas [18], too.
Advancements in treatment partly or largely account
for the improved survival of testicular cancer [19, 20],
leukaemias in childhood, yound and middle age up to
age 60 [21-24], as well as lymphomas [20], and may have
had some impact on breast [25-27] and perhaps ovarian
[28] cancer survival, too. Thus, for breast cancer appre-
ciable improvements in survival have been observed over
the last few years through screening and improved
diagnosis [29], as well as improved treatment, including
essentially adjuvant treatment for early stage breast
cancer, both node negative and positive [25, 26, 30].
However, it is more difficult to explain, through
improved diagnosis and earlier detection, as well as
through therapeutic advancements, the increased survival
estimates observed for stomach, colorectal, as well as for
lung cancer, although some impact of earlier diagnosis
may have been observed for these neoplasms, too [31,
32]. For most of these neoplasms, in any case, there is
little basis for suggesting a substantial advancement in
treatment. It is in any case not possible to provide, for
any single neoplasm, a quantification of the potential
impact of changed diagnosis and treatment on long-
term survival. Survival, however, remains unfavourable
for several cancer sites, including oesophagus, liver,
pancreas and brain.
The rise in relative survival estimates over a five-year
calendar period of 6 to 8% in this Swiss population was
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Table 4. Five-year relative survival rates from various cancers according to age at diagnosis and calendar period
Cancer site
Mouth or pharynx
Oesophagus
Stomach
Colon
Rectum
Liver
Gallbladder and biliary tract
Pancreas
Larynx
Trachea, bronchus and lung
Bone
Connective tissue
Melanomalous skin cancer
Non-melanomatous skin cancer
Breast (females)
Cervix uteri
Corpus uteri
Ovary
Prostate
Testis
Bladder
Kidney and renal pelvis
Brain
Thyroid
Non-Hodgkin lymphomas
Hodgkin's disease
Multiple myeloma
Leukaemia
Unknown origin
Total, all cancers
Total, skin non-melanoma excluded
Age group
< 60 years
1974-1978
0.46
0.07
0.34
0.61
0.55
0.10
0.24
0.06
0.69
0.13
0.62
0.55
0.72
0.97
0.67
0.74
0.83
0.37
0.39
0.74
0.39
0.49
0.29
0.91
0.48
0.68
0.57
0.29
0.22
0.57
0.50
1984-1988
0.40
0.16
0.28
0.59
0.56
0.04
0.28
0 04
0.73
0.10
071
0.71
0.83
0.97
0.75
0.73
0 87
0.50
0.69
0.91
0.64
0.61
0.40
0.98
0 72
0.88
0.49
0.52
0.15
0.66
0.57
1989-1993
0.46
0.13
0.38
0.63
0.54
0.21
0.18
0.09
0.64
0.18
0.54
0.50
0.93
0.97
0.83
0.76
0.92
0.58
0.71
0.96
0.57
0.64
0 29
0.94
0.78
0.85
0.60
0.50
0.16
0.71
0.62
^ 60 years
1974-1978
031
0.07
0.18
0.45
0.42
0.03
0.13
0.03
0.65
0.06
0.30
0.73
0.60
0.94
0.67
0.52
0.64
0.19
0.44
0.63
0 28
0.36
0.10
0.50
0.28
0.24
0.24
0.26
0.14
0.47
0.35
1984-1988
0.41
0.05
0.17
0.48
0.44
0.13
011
0.00
0.77
0.11
0.58
0.64
0.80
0.97
0.79
0.52
0.74
0.24
0.48
0.58
0.44
0.38
0.02
0.88
0.49
0.30
0.29
0.30
0.06
0.55
0.40
1989-1993
0.41
0.07
0.22
0.53
0.50
0.04
0.10
0.02
0.63
0.10
0.78
0.72
0.83
0.99
0.78
0 63
0.11
0 25
0.66
NAa
0.48
0.56
0.02
0.55
0.52
0.45
0.25
0.31
0.07
0.61
0 45
" Probability not assessable.
Results from Vaud Cancer Registry, Switzerland. 1974-1993.
apparently greater than the 3% registered in England
and Wales between cancers registered in 1981-1985 and
those registered in 1986-1990 [33]. Any between country
comparison, however, has to be taken with utmost
caution, both for absolute rates and for trends over time,
given the different standard and the variable changes in
cancer diagnosis and registrations across various popu-
lations [7, 34]. These cautions notwithstanding, survival
estimates for most cancer sites in this Swiss population
are comparable to the US SEER dataset [4] and the
most recent study from the Finnish cancer registration
system [5], and similar or somewhat higher than those
reported from European cancer registration systems [6],
indicating that the standards of diagnosis and registra-
tion are satisfactory and comparatively elevated in this
population.
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